| Objective:Meta-analysis was used to evaluate the efficacy of liraglutide in type2 diabetes(T2DM)combined with nonalcoholic fatty liver(NAFLD).Provide evidence-based medical evidence for clinical use.Methods:By searching Pubumed,Embase,Wanfang,HowNet,and Weipu database to establish a randomized case-control study related to T2DM and NAFLD in2018,the final standard,literature,and screening were obtained after screening,weighting,and reading.Quality evaluation,data extraction,and multi-person evaluation were conducted on the selected literature,and the inconsistency of the results was discussed.The weighted mean difference(WMD)value and the 95%confidence interval of the outcome indicators in the lilaglutide group and the control group were used as the effect indicators,and the randomized or fixed effect models were used for quantitative analysis.Using the review manager 5.3 software for literature heterogeneity testing,meta-analysis,if the heterogeneity is large,sensitivity analysis,sub-group analysis is needed to discuss the source of heterogeneity.Results:1.In the liraglutide group,the LFC level of the control group was less heterogeneous(heterogeneity test I~2=0),and the fixed effect model was combined with the effector WMD.The combined effect of WMD was-5.84,and its 95%CI(-7.58,-4.10),the test of the combined effect amount Z=6.58,P<0.0001.Based on this result,it can be seen that the WRL level of LFC is statistically different in the liraglutide group compared with the control group,and 95%CI falls on the left side of the ineffective vertical line,indicating that the LRC level of the liraglutide group is lower than that of the control group.Therefore,liraglutide can significantly reduce LFC levels in patients with T2DM and NAFLD compared with the control group.Compared with the control group,the level of B-level scores in the liraglutide group was less heterogeneous(heterogeneity test I~2=0),and the fixed effect model combined with the effect amount WMD,the combined effect of WMD was-0.98,95%of which CI(-1.13,-0.83),test for combined effect quantities Z=12.68,P<0.00001.Based on this result,it was found that the level of WMD in the B-ultrasound score was statistically different from that in the control group,and the 95%CI of the group was on the left side of the ineffective vertical line,indicating that the level of B-level of the liraglutide group was super-score.Lower than the control group,therefore,liraglutide can significantly reduce the B-ultrasound scores of patients with T2DM and NAFLD compared with the control group.The LRC and B-level changes indicated that the liraglutide group compared with the control group significantly reduced liver fat levels in patients with T2DM and NAFLD.2.Compared with the control group,the liraglutide group had a smaller heterogeneity(heterogeneity test I~2=24),and the fixed effect model combined with the effector WMD.The combined effect of WMD was-0.52,and its 95%CI(-0.61,-0.44),the test of the combined effect amount Z=12.20,P<0.00001.Based on this result,it can be seen that the level of WMD of TG level is statistically different in the liraglutide group compared with the control group,and95%CI falls on the left side of the inactive vertical line,indicating that the TG level of the liraglutide group is lower than that of the control group.Therefore,liraglutide can significantly reduce TG levels in patients with T2DM and NAFLD compared with the control group.3.Compared with the control group,the liraglutide group had a smaller heterogeneity(heterogeneity test I~2=0),and the fixed effect model combined with the effector WMD,the combined effect of WMD was-1.42,95%CI(-1.54,-1.31),the test of the combined effect amount Z=24.54,P<0.00001.Based on this result,it can be seen that compared with the control group,the WRD of TC level was statistically different,and the 95%CI of the lysal group was on the left side of the inactive vertical line,indicating that the TC level of the liraglutide group was lower than that of the control group.Therefore,liraglutide can significantly reduce TC levels in patients with T2DM and NAFLD compared with the control group.4.The liraglutide group compared the ALT level of the control group,and the 95%confidence interval of the four studies intersected the ineffective vertical line,indicating that the four groups of studies concluded that there was no difference in the mean ALT level between the liraglutide group and the control group.That means that there was no statistically significant difference in ALT levels between the liraglutide group and the control group.5.The liraglutide group compared with the control group AST level study,in which the 95%confidence interval of the four studies intersected the ineffective vertical line,indicating that the four groups of studies concluded that there was no difference in the ALT level between the liraglutide group and the control group.That is,there is no statistically significant difference in AST levels between the liraglutide group and the control group.6.Compared with the control group,the level of HbA1C in the liraglutide group was highly heterogeneous(heterogeneity test I~2=92),and the random effect model combined effect amount WMD,the combined effect of WMD was-1.44,95%CI(-2.23,-0.64),the test of the combined effect amount Z=3.56,P=0.0004.Based on this result,it can be seen that the WLa of HbA1C level was statistically different in the liraglutide group compared with the control group,and95%CI of the group was on the left side of the inactive vertical line,indicating that the level of HbA1C in the liraglutide group was lower than that in the control group.Therefore,liraglutide can significantly reduce HbA1C levels in patients with T2DM and NAFLD compared with the control group.Conclusions:This meta-analysis confirmed that liraglutide has a significant effect on T2DM combined with NAFLD,and that liraglutide can significantly reduce liver fat content,blood lipids and blood glucose in patients with T2DM and NAFLD. |
PDF Full Text Request